Compare Enveric Biosciences Inc (ENVB) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Ferrari NV — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Ferrari NV trades at $389.91 (market cap $67.35B). The key difference: Ferrari NV is far larger — about 9904.4× Enveric Biosciences Inc's market cap, and Ferrari NV pays a 1.09% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Ferrari NV for 126 Days on average.
| ENVB | RACE | |
|---|---|---|
Market Cap | $6.80M | $67.35B |
Volume | 64,867 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $436.54 |
52-Week Low | $1.27 | $314.63 |
Typical Hold Time | 14 Days | 126 Days |
Enterprise Value | -$1.49M | $69.22B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
Ferrari (RACE) trades at $388.77, up 0.62% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15 billion in 2025, and net income margin remains robust at 22.25%. The company is executing a share buyback program and expanding partnerships, such as with Rakuten effective 2027.
The outlook is positive given analyst consensus of $462.75 price target and 73.69% buy ratings. Risks include high valuation multiples and exposure to economic cycles. Institutional interest is rising, but technical indicators suggest near-term resistance at $390.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
